Table 4 Clinical application of nanoparticles in the treatment of lung cancer
From: Nanoparticles advanced from preclinical studies to clinical trials for lung cancer therapy
Nanoparticle-Based Drugs | Other drugs | Allocation | Way of administration | Serious adverse reactions | Stage | State | Numbering |
|---|---|---|---|---|---|---|---|
Nab-paclitaxel | TKI | Not applicable | Intravenous injection of nab-paclitaxel over 30Â min on d1, d8, and d15 | 3.85% (1/26) | Phase II | Completed | NCT01620190 |
Nab-paclitaxel | Carboplatin; Erlotinib Hydrochloride | Not applicable | Intravenous injection of nab-paclitaxel for 30Â min on day 1 d1 intravenous carboplatin 30Â min Oral erlotinib hydrochloride after d43, once daily | 25.33% (19/75) | Phase II | Completed | NCT00553462 |
Nab-paclitaxel | Carboplatin | Not applicable | On day 1, intravenous injection of nab-paclitaxel for 30 min, carboplatin for 1–2 h | 3.17% (2/63) | Phase II | Completed | NCT00729612 |
Nab-paclitaxel | Carboplatin | Not applicable | d1, d8, d15, d22, d29, d36, d43 intravenous injection of nab-paclitaxel and carboplatin, respectively | I: 50% (5/10) II: 50% (1/2) | Phase I II | Termination | NCT00544648 |
Nab-paclitaxel | Carboplatin; Pembrolizumab | Random | Intravenous pembrolizumab before chemotherapy, nab-paclitaxel and carboplatin intravenously on day 1 | 40.65% (113/278) | Phase III | Active, not recruiting | NCT02775435 |
Nab-paclitaxel | Carboplatin; Pembrolizumab | Random | Intravenous pembrolizumab before chemotherapy, nab-paclitaxel and carboplatin intravenously on day 1 | 52.31% (34/65) | Phase III | Active, not recruiting | NCT03875092 |
Nab-paclitaxel | Pemetrexed | Non-random | I: Intravenous injection of nab-paclitaxel for more than 30Â min, pemetrexed for more than 10Â min II: Receive the same phase I drugs within the MTD range | I: 8.33% (1/12) II: 16.22% (6/37) | Phase I II | Termination | NCT00470548 |
CRLX101 | Â | Random | CRLX101 was administered intravenously at 15Â mg/m2 every other week | 12.37% (12/97) | Phase II | Completed | NCT01380769 |
ABI-009 | Â | Not applicable | Intravenous injection of ABI-009 on d1 and d8 | 60.00% (3/5) | Phase II | Termination | NCT03670030 |